Physician profile
Taylor W Bladh
NPI 1467527028
$7,049.02
in general payments reported to CMS, 2019-2025
18 companies · $1,439 in 2025
The $1,439 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,300 · 2020: $58.12 · 2021: $329 · 2022: $429 · 2023: $2,071 · 2024: $423 · 2025: $1,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,939 · Travel and Lodging: $887 · Entertainment: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,939.32 |
| Travel and Lodging | $886.76 |
| Entertainment | $106.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,215.64 | 2019-2021 | |
| Alcon Vision LLC | $1,910.75 | 2019-2025 | Air Optix, Dailies Aqua Comfort Plus, Dailies Total1 Multifocal |
| Coopervision INC. | $498.93 | 2021-2025 | Misight Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $424.21 | 2022-2025 | Infuse, Xiidra, Miebo |
| Johnson & Johnson Vision Care, INC. | $344.08 | 2019-2023 | Acuvue |
| Glaukos Corporation | $305.84 | 2021-2024 | Photrexa |
| Tarsus Pharmaceuticals, INC. | $292.09 | 2025 | Xdemvy |
| Dompe US, INC. | $205.25 | 2022-2025 | Oxervate |
| Oyster Point Pharma, INC. | $195.07 | 2022-2023 | Tyrvaya |
| Nova Eye, INC. | $125.00 | 2025 | |
| Optos, INC. | $106.38 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Sight Sciences, INC. | $100.00 | 2023 | Tearcare System |
| Sun Pharmaceutical Industries INC. | $90.30 | 2020-2021 | |
| Biotissue Holdings INC. | $89.46 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $54.95 | 2022-2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $46.80 | 2021-2022 | |
| Optovue, INC. | $31.25 | 2019 | |
| Abb Con-Cise Optical Group LLC | $13.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Bladh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.